187 related articles for article (PubMed ID: 24859996)
1. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?
Kondo M; Murakawa Y; Matsumura T; Matsumoto O; Taira M; Moriyama M; Sumita Y; Yamaguchi S
Rheumatology (Oxford); 2014 Oct; 53(10):1907-8. PubMed ID: 24859996
[No Abstract] [Full Text] [Related]
2. A case of bilateral rheumatoid pleuritis successfully treated with tocilizumab.
Ohtsuka K; Takeuchi K; Matsushita M; Aramaki T
Mod Rheumatol; 2014 Nov; 24(6):1001-4. PubMed ID: 24533552
[TBL] [Abstract][Full Text] [Related]
3. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma.
Liozon E; Ouattara B; Loustaud-Ratti V; Vidal E
Scand J Rheumatol; 2007; 36(6):484-6. PubMed ID: 18092275
[No Abstract] [Full Text] [Related]
4. Overlap of systemic sclerosis and rheumatoid arthritis.
Alkassab F
J Rheumatol; 2007 Jul; 34(7):1593-4. PubMed ID: 17611965
[No Abstract] [Full Text] [Related]
5. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
6. A case report of a patient with rheumatoid arthritis complicated with Mycobacterium avium during tocilizumab treatment.
Nakahara H; Kamide Y; Hamano Y; Hosokawa T; Nishide M; Lin Y; Kawamoto K; Fusama M; Higa S; Kuroiwa T; Igarashi T; Kuritani T; Maeda K
Mod Rheumatol; 2011 Dec; 21(6):655-9. PubMed ID: 21484291
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study).
Mori S; Yoshitama T; Hidaka T; Hirakata N; Ueki Y
Ann Rheum Dis; 2015 Mar; 74(3):627-30. PubMed ID: 25561361
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection.
Giannitti C; Fineschi I; Frediani B; Fioravanti A; Galeazzi M
Clin Exp Rheumatol; 2013; 31(5):816. PubMed ID: 24021246
[No Abstract] [Full Text] [Related]
9. [Connective tissue diseases].
Lorenz HM
Dtsch Med Wochenschr; 2012 Mar; 137(13):661-3. PubMed ID: 22434176
[No Abstract] [Full Text] [Related]
10. [Adalimumab induced-inflammatory myopathy in rheumatoid arthritis].
de Souza FH; Barros TB; Levy-Neto M; Shinjo SK
Acta Reumatol Port; 2012; 37(2):180-3. PubMed ID: 23149641
[TBL] [Abstract][Full Text] [Related]
11. Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years.
Suzuki T; Hirota T; Ogishima H; Umeda N; Kondo Y; Yokosawa M; Miki H; Tsuboi H; Matsumoto I; Sumida T
Int J Rheum Dis; 2015 Jan; 18(1):108-10. PubMed ID: 25294091
[No Abstract] [Full Text] [Related]
12. Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritis.
Mori S
Mod Rheumatol; 2012 Nov; 22(6):947-50. PubMed ID: 22350573
[No Abstract] [Full Text] [Related]
13. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B.
Tsuboi H; Tsujii A; Nampei A; Yoshihara H; Kawano K; Takeuchi E; Shi K
Mod Rheumatol; 2011 Dec; 21(6):701-5. PubMed ID: 21626075
[TBL] [Abstract][Full Text] [Related]
14. Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: preliminary results.
Benucci M; Manfredi M; Saviola G; Sarzi-Puttini P; Atzeni F
Clin Exp Rheumatol; 2013; 31(2):322-3. PubMed ID: 23380047
[No Abstract] [Full Text] [Related]
15. Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis.
Kono M; Yasuda S; Kono M; Atsumi T
Scand J Rheumatol; 2018 May; 47(3):248-250. PubMed ID: 28480784
[No Abstract] [Full Text] [Related]
16. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Elhai M; Meunier M; Matucci-Cerinic M; Maurer B; Riemekasten G; Leturcq T; Pellerito R; Von Mühlen CA; Vacca A; Airo P; Bartoli F; Fiori G; Bokarewa M; Riccieri V; Becker M; Avouac J; Müller-Ladner U; Distler O; Allanore Y;
Ann Rheum Dis; 2013 Jul; 72(7):1217-20. PubMed ID: 23253926
[TBL] [Abstract][Full Text] [Related]
17. Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
Brunasso AM; Scocco GL; Massone C
J Rheumatol; 2010 Jul; 37(7):1549-50. PubMed ID: 20595297
[No Abstract] [Full Text] [Related]
18. Is rituximab an effective treatment of refractory calcinosis?
Dubos M; Ly K; Martel C; Fauchais AL
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27247203
[TBL] [Abstract][Full Text] [Related]
19. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks.
Yokoe I; Nishio S; Sato H; Kobayashi H
Mod Rheumatol; 2011 Dec; 21(6):710-4. PubMed ID: 21656090
[No Abstract] [Full Text] [Related]
20. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
